Literature DB >> 33816680

Neuronuclear and Neuromelanin-Sensitive Imaging for Acquired Hepatocerebral Degeneration with Parkinsonism.

Takashi Ogawa1, Kotaro Ogaki1,2, Yuko Mori1, Hikaru Kamo1, Akira Uchiyama3, Koji Kamagata4, Masanori Nagaoka1, Nobutaka Hattori1.   

Abstract

Entities:  

Keywords:  acquired hepatocerebral degeneration; dopamine transporter imaging; levodopa responsive parkinsonism; neuromelanin‐sensitive imaging; primary biliary cholangitis

Year:  2021        PMID： 33816680      PMCID： PMC8015886          DOI： 10.1002/mdc3.13166

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


× No keyword cloud information.
  14 in total

1.  Dopaminergic neuronal integrity in parkinsonism associated with liver cirrhosis.

Authors:  Jong-Min Kim; Ji Seon Kim; Sook-Hyang Jeong; Yu Kyeong Kim; Sang Eun Kim; Suk Hwan Kim; Yangho Kim
Journal:  Neurotoxicology       Date:  2010-05-08       Impact factor: 4.294

Review 2.  Acquired hepatocerebral degeneration.

Authors:  Joseph Ferrara; Joseph Jankovic
Journal:  J Neurol       Date:  2009-02-17       Impact factor: 4.849

3.  Altered striatal dopamine D2 receptor density and dopamine transport in a patient with hepatic encephalopathy.

Authors:  K Weissenborn; G Berding; H Köstler
Journal:  Metab Brain Dis       Date:  2000-09       Impact factor: 3.584

4.  Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levels.

Authors:  Susan R Criswell; Joel S Perlmutter; Jeffrey S Crippin; Tom O Videen; Stephen M Moerlein; Hubert P Flores; Angela M Birke; Brad A Racette
Journal:  Arch Neurol       Date:  2012-03

5.  18F-FP-CIT dopamine transporter PET findings in cirrhotic patients with parkinsonism.

Authors:  Hui-Jun Yang; Seol Hoon Park; Minjung Seo; Young Cheol Weon; Yangho Kim
Journal:  Neurotoxicology       Date:  2017-03-01       Impact factor: 4.294

6.  Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease.

Authors:  Daisuke Taniguchi; Taku Hatano; Koji Kamagata; Ayami Okuzumi; Yutaka Oji; Akio Mori; Masaaki Hori; Shigeki Aoki; Nobutaka Hattori
Journal:  Mov Disord       Date:  2018-05-14       Impact factor: 10.338

7.  Cirrhosis-related Parkinsonism: prevalence, mechanisms and response to treatments.

Authors:  Anita B Tryc; Annemarie Goldbecker; Georg Berding; Stefan Rümke; Kambiz Afshar; Golschan Hamidi Shahrezaei; Henning Pflugrad; Hannelore Barg-Hock; Christian P Strassburg; Hartmut Hecker; Karin Weissenborn
Journal:  J Hepatol       Date:  2012-12-05       Impact factor: 25.083

8.  Clinical and neuroradiological improvement in chronic acquired hepatocerebral degeneration after branched-chain amino acid therapy.

Authors:  Y Ueki; E Isozaki; Y Miyazaki; R Koide; T Shimizu; K Yagi; S Hirai
Journal:  Acta Neurol Scand       Date:  2002-08       Impact factor: 3.209

9.  SPECT follow-up study of cerebral blood flow changes during Donepezil therapy in patients with Alzheimer's disease.

Authors:  Soichiro Shimizu; Haruo Hanyu; Toshihiko Iwamoto; Kiyoshi Koizumi; Kimihiko Abe
Journal:  J Neuroimaging       Date:  2006-01       Impact factor: 2.486

Review 10.  Recent Updates on Acquired Hepatocerebral Degeneration.

Authors:  Hae-Won Shin; Hee Kyung Park
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.